Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

receptor affinity is a starting point in most successful drug development programs, but we know that selectivity, bioavailability, PK etc all contribute to the usefulness (or not) of a drug.
Here is a snippet of usefull info:

Hilarious. The quote is the exact same quote I've pasted and linked to already today. Funnily enough, it hasn't changed and still supports everything I've been saying. Nice try.


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145719368


And I agree, "receptor affinity is a starting point," and based on the receptor studies and other epidemiological and animal studies, iradipine was determined the best candidate to move forward and then successfully completed Phase 2 and Phase 3, unlike any other CCB for PD.


Man, this is so easy.